VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...
Live Mint on MSN7h
Alembic Pharma Q3 Results: Consolidated net profit declines 23% to ₹138 crore, stock down 5%Alembic Pharmaceuticals reported a 23.29% decline in Q3 FY25 net profit at ₹138.42 crore, despite a 3.81% revenue increase to ...
Alembic Pharmaceuticals tumbled 3.43% to Rs 905 after the company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24.
INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...
With pharmaceutical companies heavily investing in R&D and precision medicine, the demand for high-quality specialty APIs is ...
INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a ...
Drug maker Alembic Pharma on Monday reported Rs 138 crore net profit in Q3FY25, which is 23% year-on-year (YoY) decline ...
Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...
The global protein a resins industry is experiencing unprecedented growth, with projections indicating a significant increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback